Date Title Description PDF
27 Feb 2024 About Corporate Governance The Company informs about the agreements adopted by the Board of Directors Download
08 Nov 2023 On P&L The Company releases the press release related to the first nine months of 2023 financial results Download
08 Nov 2023 On P&L The Company releases the first nine months 2023 financial results presentation Download
26 Jul 2023 On buy-back programmes The Company reports the commencement, effective as of today, 26 July 2023, of a share buyback program.   Download
26 Jul 2023 On P&L The Company releases the press release related to the first half 2023 financial results Download

Pages

Date Title Description PDF
28 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 23 February 2022 and 25 February 2022 Download
23 Feb 2022 Annual Corporate Governance Report ROVI releases the 2021 Annual Corporate Governance Report Download
23 Feb 2022 Annual Report regarding remuneration of the members of the Board of Directors ROVI releases the 2021 annual report regarding remuneration of the members of the Board of Directors Download
21 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 14 February 2022 and 21 February 2022 Download
15 Feb 2022 On business and financial situation ROVI has announced that the European Commission has authorised the marketing of Okedi® for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. Download

Pages

Date Title Description PDF
07 Nov 2011 Otros sobre Gobierno Corporativo Download
19 Oct 2011 I+D resultados obtenidos; licencias, patentes y marcas Download
26 Sep 2011 Acuerdos estratégicos con terceros Download
23 Sep 2011 Acuerdos estratégicos con terceros Download

Pages